Lee, Hyun-ju
Hwang, Jeong-Woo
Park, Jin-Hee
Jeong, Yoo Joo
Jang, Ji-Yeong
Hoe, Hyang-Sook http://orcid.org/0000-0001-8877-8594
Funding for this research was provided by:
KBRI (23-BR-02-03, 23-BR-03-05, 23-BR-05-02, 23-BR-03-01, 23-BR-03-07, 23-BR-02-12)
Article History
Received: 18 June 2023
Accepted: 4 August 2023
First Online: 14 August 2023
Declarations
:
: All in vivo experiments were approved by the institutional biosafety committee (IBC) and were performed in accordance with approved animal protocols and guidelines established by the institutional animal care and use committee of Korea Brain Research Institute (KBRI, approval numbers: IACUC-19–00049 and IACUC-22–00044).
: Not applicable.
: The patents regarding the efficacy of ibrutinib on AD pathology were licensed to PharmacoRex on March 3, 2023.